X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ALKEM LABORATORIES VENUS REMEDIES/
ALKEM LABORATORIES
 
P/E (TTM) x -911.2 - - View Chart
P/BV x 0.3 6.8 3.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   ALKEM LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ALKEM LABORATORIES
Mar-16
VENUS REMEDIES/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2181,589 13.7%   
Low Rs821,232 6.7%   
Sales per share (Unadj.) Rs365.6417.5 87.6%  
Earnings per share (Unadj.) Rs1.556.3 2.6%  
Cash flow per share (Unadj.) Rs37.964.7 58.6%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs382.5292.9 130.6%  
Shares outstanding (eoy) m11.44119.57 9.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.4 12.1%   
Avg P/E ratio x101.025.1 403.0%  
P/CF ratio (eoy) x4.021.8 18.2%  
Price / Book Value ratio x0.44.8 8.1%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m1,717168,653 1.0%   
No. of employees `0001.0NA-   
Total wages/salary Rs m3249,171 3.5%   
Avg. sales/employee Rs Th4,100.7NM-  
Avg. wages/employee Rs Th318.0NM-  
Avg. net profit/employee Rs Th16.7NM-  
INCOME DATA
Net Sales Rs m4,18349,915 8.4%  
Other income Rs m201,645 1.2%   
Total revenues Rs m4,20351,561 8.2%   
Gross profit Rs m8128,482 9.6%  
Depreciation Rs m4171,006 41.4%   
Interest Rs m380671 56.6%   
Profit before tax Rs m358,451 0.4%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m181,606 1.1%   
Profit after tax Rs m176,731 0.3%  
Gross profit margin %19.417.0 114.2%  
Effective tax rate %51.619.0 271.4%   
Net profit margin %0.413.5 3.0%  
BALANCE SHEET DATA
Current assets Rs m2,77127,062 10.2%   
Current liabilities Rs m1,93115,324 12.6%   
Net working cap to sales %20.123.5 85.3%  
Current ratio x1.41.8 81.2%  
Inventory Days Days12567 188.0%  
Debtors Days Days5441 130.2%  
Net fixed assets Rs m5,32812,610 42.3%   
Share capital Rs m114239 47.8%   
"Free" reserves Rs m4,17734,490 12.1%   
Net worth Rs m4,37635,027 12.5%   
Long term debt Rs m1,9111,212 157.7%   
Total assets Rs m8,42854,387 15.5%  
Interest coverage x1.113.6 8.0%   
Debt to equity ratio x0.40 1,262.1%  
Sales to assets ratio x0.50.9 54.1%   
Return on assets %4.713.6 34.6%  
Return on equity %0.419.2 2.0%  
Return on capital %6.624.9 26.6%  
Exports to sales %012.9 0.0%   
Imports to sales %20.53.1 665.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs m8581,540 55.7%   
Fx inflow Rs m06,563 0.0%   
Fx outflow Rs m8583,012 28.5%   
Net fx Rs m-8583,552 -24.2%   
CASH FLOW
From Operations Rs m4697,259 6.5%  
From Investments Rs m291,864 1.6%  
From Financial Activity Rs m-464-9,273 5.0%  
Net Cashflow Rs m35-150 -23.0%  

Share Holding

Indian Promoters % 32.9 66.9 49.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 33.1 0.5%  
FIIs % 0.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 0.0 -  
Shareholders   20,121 68,381 29.4%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Consumer Durables Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed buying activity throughout the day and ended the day on a positive note.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 24, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS